{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216723","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2026-05-11T20:05:14+00:00","discovered_at":"2026-05-11T20:07:00.351027+00:00","generated_at":"2026-05-11T22:53:35.214230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Septerna reports Q1 net loss $8.6M; cash $522M; positive Phase 1 data for SEP-631","bullets":["Revenue from Novo Nordisk collaboration $26.5M; net loss improved to $8.6M from $21.5M YoY.","Cash $522.1M as of March 31, 2026; expected runway into 2029.","SEP-631 Phase 1 positive: well tolerated, supports once-daily dosing; Phase 2b in CSU planned H2 2026.","SEP-479 Phase 1 trial for hypoparathyroidism initiated; data expected late 2026/early 2027.","CMO Jae Kim departing; successor search initiated; will serve advisory role during transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216723","json":"https://secwatch.observer/filing/0001193125-26-216723.json","markdown":"https://secwatch.observer/filing/0001193125-26-216723.md","text":"https://secwatch.observer/filing/0001193125-26-216723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526216723/0001193125-26-216723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526216723/sepn-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:53:35.214230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}